Categories
News

Market mover Predictmedix offers COVID-19 mass screening and now — a telemedicine platform

As COVID-19 global cases move towards 10 million (currently 8.26 million) one company now offers COVID-19 mass screening using a revolutionary form of Artificial Intelligence (AI). The technology also works for infection screening, sobriety testing and various other medical conditions such as mental disorders (depression & dementia). Early adopters are companies wanting to safeguard their workers as well as healthcare operations wanting to keep their premises safe from COVID-19 infection. The technology is suitable for large scale screening by governments, law enforcement, healthcare, other organizations, and employers worldwide.

That company is Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). Predictmedix has developed a disruptive AI technology that is leading the future in impairment detection and healthcare screenings. Predictmedix‘s AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are impaired or suffering from infectious disease or mental illness.

Continue reading the article here.

Categories
News

BlogTO: Toronto artificial intelligence startup creates disease screening tool for retail stores

An artificial intelligence development company out of Toronto has introduced some fancy new tools to help businesses operate more safely during the pandemic.

Predictmedix‘s technologies allow stores and other establishments to screen customers for symptoms of COVID-19 before they enter, and they can even tell when people aren’t properly social distancing or wearing masks while inside.

The firm’s Infection and Protocol Screening machines — which take the form of standalone pods or walk-through booths — use AI, infrared thermography and multispectral cameras to detect symptoms within seconds, and can even recognize cognitive impairment from substances like alcohol or illnesses like dementia.

Continue reading the article here.

Categories
News

Predictmedix Inc. Announces a Major North American Sales Contract with Juiceworks Exhibits for its COVID-19 Mass Screening Technology

May 20, 2020 (Source) – Predictmedix announces its first significant North American sales contract

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce the execution of a sales contract for its COVID-19 screening technology with Juiceworks Exhibits (“Juiceworks”), a full-service design and build company that creates brand experiences for leading brands across North America with operations both in Canada and the USA.

Utilizing Predictmedix COVID-19 mass screening technology, Juiceworks is offering safe indoor/outdoor entry solutions using custom-fabricated temporary structures. All of the entry solutions being sold by Juiceworks across North America will be retrofitted with Predictmedix technology for COVID-19 mass screening.

Continue reading the article here.